Clinical Trial: Flonoltinib Maleate for the Treatment of Patients With Intermediate- or High-risk Myelofibrosis Who Are Refractory, Relapsed, or Intolerant to JAK Inhibitors a Single-arm, Open-label, Multicenter Phase IIb Clinical Trial Evaluating Efficacy and Safety

U.S., March 3 -- ClinicalTrials.gov registry received information related to the study (NCT07443306) titled 'Flonoltinib Maleate for the Treatment of Patients With Intermediate- or High-risk Myelofibrosis Who Are Refractory, Relapsed, or Intolerant to JAK Inhibitors a Single-arm, Open-label, Multicenter Phase IIb Clinical Trial Evaluating Efficacy and Safety' on Dec. 19, 2025.

Brief Summary: This trial adopts a single arm, open label, multi center clinical trial design, with a planned enrollment of approximately 64 participants in the moderate to high risk MF trial who are refractory, relapsed, or intolerant to Ruxolitinib . Select successful trial participants and allocate flonoltinib maleate tablets based on platelet count levels during ...